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Available online 5 November 2016Endometriosis, the hormone-dependent extrauterine dissemination of endometrial tissue outside the uterus,
affects 5–15% of women of reproductive age. Pathogenesis remains poorly understood as well as the estrogen
production by endometriotic tissue yielding autocrine growth. Estrogens (E2) are normally produced by the
ovaries. We investigated whether aberrant “ovarian-like” differentiation occurred in endometriosis.
69 women, with (n= 38) and without (n= 31) histologically proven endometriosis were recruited. Compara-
tiveRT-qPCRwasperformed on 20 genes in paired eutopic and ectopic lesions, togetherwith immunohistochem-
istry. Functional studies were performed in primary cultures of epithelial endometriotic cells (EEC).
A broaden ovarian-like differentiation was found in half eutopic and all ectopic endometriosis with aberrant
expression of transcripts and protein for the transcription factors GATA4 and GATA6 triggering ovarian differen-
tiation, for the FSH receptor (FSHR) and the ovarian hormone INSL3. Like in ovaries the FSHR induced aromatase,
the key enzyme in E2 production, and vascular factors in EEC. The LH receptor (LHR) was also aberrantly
expressed in a subset of ectopic endometriosis (21%) and induced strongly androgen-synthesizing enzymes
and INSL3 in EEC, as in ovaries, as well as endometriotic cell growth. The ERK pathway mediates signaling by
both hormones. A positive feedback loop occurred through FSHR and LHR-dependent induction of GATA4/6 in
EEC, as in ovaries, enhancing the production of the steroidogenic cascade.
This work highlights a novel pathophysiological mechanism with a broadly ovarian pattern of differentiation in
half eutopic and all ectopic endometriosis. This study provides new tools that might improve the diagnosis of
endometriosis in the future.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Ovarian- like differentiation1. Introduction
Endometriosis, characterized by the extrauterine dissemination of
endometrial tissue, is a major public health problem affecting 5–15%
of women of reproductive age. It has an incidence of up to 50% in
women seeking treatment for pain and infertility, places a large
economic burden on countries throughout theworld and is functionally
debilitating for affected women. The pathogenesis of endometriosis isSubfamily A Member 1; CYP17,
19A1, Cytochrome P450 Family
otic Cells; EGVEGF, Endocrine
4/6, GATA binding protein 4/6;
tor; FSHR, Follicle Stimulating
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tion quantitative Polymerase
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Vincent de Paul, Service de
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. This is an open access article understill poorly understood but it is known to be a hormone-dependent dis-
ease. The survival and proliferation of lesions is dependent on estrogens
(E2) produced by endometriotic implantswhich acquire aberrant endo-
crine function. E2 induces autocrine and paracrine growth pathways.
This chronic disease is often diagnosed late, about 7–10 years after the
apparition of the ﬁrst symptoms during surgery [1–4] when lesions
have already disseminated in the pelvis. There is no early non-invasive
marker predicting the development of the disease. Endometriosis is
considered benign disease, but has features common with cancers,
such as progressive estrogen-dependent proliferation, peritoneal and
pelvic invasion, associated with chronic inﬂammation and angiogenesis
[1,5]. The primary mechanism of action of hormone therapy for endo-
metriosis is the inhibition of estrogen production [2,3,6].
The mechanisms underlying the abnormal production of estrogens
by endometriotic tissue are poorly understood. Inﬂammation is thought
to be responsible for overexpression of the Steroidogenic Factor-1 (SF1)
transcription factor and in situ E2 production in endometriosis [1].
However, E2 is normally produced by the ovary. The FSH receptor
(FSHR) and LH receptor (LHR) play a critical role in this process by
inducing respectively aromatase, which converts androgens intothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of androgens, which serve as substrates for aromatase [7]. This
raises questions about the role of the FSHR and LHR in controlling
endometriotic steroidogenesis and whether more general aberrant
“ovarian-like” differentiation occurs in endometriosis.
Angiogenesis of the endometriotic cells in implanted places appears
to be essential for the survival and development of endometriotic cells,
as already reported for tumor growth [2]. FSHR is also expressed in
tumor blood vessels [8] and most metastases [9]. It is thought to
stimulate angiogenesis, thereby favoring tumorigenesis.
We investigate a possible “ovarian-like” differentiation in endome-
triosis. We thus studied FSHR and LHR expression in paired eutopic en-
dometrium and ectopic lesions of patients with endometriosis by RT-
qPCR and immunohistochemistry using monoclonal antibodies. To un-
derstand the aberrant expression of receptors we also studied the ex-
pression of other markers of ovarian differentiation and transcription
factors necessary for gonadotropin receptor onset in the ovary. We
also perform functional studies in primary cultures of epithelial
endometriotic cells (EEC).
2. Materials and methods
2.1. Patients and study design
All the patients studied in this work have been described in a
previous study [10]. The cohort recruited in this study consisted of 69
women with (n = 38) and without (n = 31) macroscopic
endometriotic lesions already described [10]. The patients and controls
groups were homogenous for age, gestity, parity, and phase of themen-
strual cycle with the same number of patients being in proliferative or
secretory phases [10]. All samples were histologically characterized for
patients and controls. Patients with endometriosis provided both
eutopic and ectopic endometrium. The samples were selected from 38
patients afﬂicted with painful endometriosis and operated for complete
surgical exeresis of all endometriotic lesions. Endometriosis was catego-
rized according to a previously published surgical classiﬁcation based
on the location of the worst endometriotic lesion location: superﬁcial
(SUP), endometrioma (OMA) (n = 19), and deeply inﬁltrating
endometriosis (DIE) (n = 19). Endometriosis was scored according to
the revised American Fertility Society classiﬁcation [10]. Control
endometrial specimens were collected from 31 patients without any
macroscopic endometriotic lesion as checked during a thorough surgi-
cal examination of the abdominopelvic cavity. Indications for surgery
in controlswere the following: tubal infertility, non endometriotic ovar-
ian cysts, or uterine myoma. The local ethics committee (Comité
Consultatif de Protection des Personnes dans la Recherche Biomédicale
of Paris- Cochin) approved the study protocol. All patients gave an in-
formed written consent.
2.2. Total RNA extraction, reverse transcription and RT-qPCR
We used 47 tissue samples (32 paired eutopic and ectopic
endometrioses, and 15 controls) for RT-qPCR on 17 genes of interest
and 3 control genes. The characteristics of these selected patients have
been described [10]. After surgical resection, samples of disease-free
control biopsy specimens and eutopic or ectopic endometrium biopsy
specimens were immediately frozen in liquid nitrogen. Total RNA was
extracted with Trizol (Invitrogen, Carlsbad, CA), according to the
manufacturer's instructions. RNA quality was checked by agarose gel
electrophoresis and spectrophotometry.We generated cDNA by reverse
transcribing 4 μg of total RNAwith randomprimers andM-MLV reverse
transcriptase (Invitrogen), according to themanufacturer's instructions.
We treated the cDNA with RNase before RT-PCR. The primers used for
RT-PCR analysis were selected with PRIMER3 software, on the basis of
published sequences. The primers were produced by Eurogentec
(Angers, France). Quantitative PCR was carried out on a 96-well LightCycler 480 machine (Roche Diagnostics, Manheim, Germany), with a
Light Cycler 480 SYBRGreen IMaster kit (Roche). Resultswere analyzed
with Light Cycler software, by the three-ﬁt point method. Relative
abundances in endometriotic tissues were calculated by the−2ΔΔCt
method with respect to the mean for the three control genes (mean
for 3 housekeeping genes SDHA, HPRT and HISTH1A genes) and
normalization with the mean value for a pool of genes from control
endometria. We also studied FSHR and LHR expression in 12 additional
patients with endometriosis and six supplementary controls from the
same cohort already described [10]. Sequences of primers are available
on request.
2.3. Immunohistochemistry
Immunohistochemistry was performed on 10 matched ectopic
endometriosis and 10 control disease-free endometria (for each 5 in
proliferative phase and 5 in secretory phase). The patients belong to a
cohort already described [10]. A previously described antigen retrieval
method was used [11]. Brieﬂy, the samples were embedded in parafﬁn
and 4-μm sections were cut sequentially and mounted on SuperFrost
treated slides (Menzel-Glasse, Braunschweig, Germany). The slides
were allowed to dry overnight at 37 °C. The parafﬁn was then eliminat-
ed by immersion in xylene and the sectionswere rehydrated in a graded
series of ethanol solutions. For epitope retrieval, the slides were
immersed in citrate buffer pH 6.0, in a water bath at 95 °C to 99 °C for
60 min. The slides were then allowed to cool in the buffer for 20 min
at room temperature. H2O2 (0.3%) was added to the slides, which
were then incubated at room temperature for 30 min. They were then
incubated with the primary antibodies for 2 h. The NovolLink max
Polymer Detection System (Newcastle, UK) was used for the
subsequent steps, according to the manufacturer's instructions.
Diaminobenzidine-hydrogen peroxide or aminoethyl carbazole
(Clinisciences,FR) were used for chromogenic development. The slides
were lightly counterstainedwith hematoxylin, dehydrated, and covered
with a coverslip. For control IgG, replacement of the speciﬁc primary an-
tibody was performed on serial sections incubated with corresponding
pre-immune immunoglobulins (mouse and rabbit IgG, Sigma Aldrich)
at the same concentration used for the speciﬁc primary antibody.
We controlled also for nonspeciﬁc binding of the primary antibody
preparation, by replacing the ﬁrst layer of serial sections with non spe-
ciﬁc slides. Normal human ovarian granulosa cells and/or theca cells
served as positive controls. The following antibodies were used:
monoclonal antibody against LHR (clone 29, dilution: 1/200) [12],
monoclonal antibody against FSHR (clone 323, dilution: 1/300) [12],
and polyclonal antibodies against aromatase (H4, dilution: 1/50)
(Acris Antibodies, San Diego, USA), CYP 17 A1 (M-80-SC/66850,
dilution: 1/100) (Santa Cruz Biotechnology Inc., USA), CYP11A1
(13363-1-AP, dilution 1/100) (Proteintech, USA) , INSL3 (ab65981,
dilution 1/100) (abcam, FRA), GATA6 (ab22600, dilution 1/100)
(abcam, FRA), and GATA 4 (SC:25310, dilution: 1/50) (Santa Cruz
Biotechnology Inc., USA).
2.4. Primary cultures
Primary cultures of epithelial endometriotic cells (EEC) fromwomen
with and without endometriosis were obtained from 12 consecutive
patients, as previously described [10,13]. All cells were cultured and
treated with hCG or rFSH as described [13–15]. Brieﬂy, for each of
these patients, a surgical biopsy was performed from DIE. Specimens
were collected under sterile conditions and transferred, in DMEM
(Dulbecco's modiﬁed Eagle medium, Gibco Invitrogen, Cergy Pontoise,
France), to the laboratory, where they were prepared for cell extraction
or in vivo experiments within 30 min. Biopsy specimens were rinsed,
minced into small pieces, digested with dispase and collagenase
(2 mg/ml, Gibco Invitrogen, Cergy Pontoise, France) for 1 h at 37 °C
and separated by serial ﬁltration. Red blood cells were removed by
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Na2EDTA). Debris was removed by passage through sieves with 100-
μm pores. Epithelial cells were retained on sieves with 40-μm pores,
whereas stromal cells remained in the ﬁltrate. Both cell types were
plated in Primaria 75 cm2 ﬂasks (Becton Dickinson Labware, Le Pont
de Claix, France) and cultured in DMEM with 10% FBS (fetal bovine
serum). The purity of the stromal and epithelial cell preparations was
conﬁrmed by ﬂuorescence staining in a previous study [12].
2.5. Treatments of cells and immunoblotting of cell lysates
For all in vitro experiments, cells were prepared as follows. Each cell
type was cultured in its speciﬁc medium to 90% conﬂuence. Cells were
rendered quiescent by two washes with ice-cold PBS (Invitrogen) and
incubated with serum-free medium for 12–16 h. The cells were then
left untreated or were treated with hCG or rFSH, as indicated in the
ﬁgure legends, in fresh serum-free medium. Doses and exposure times
for hCG (Gonadotrophine Chorionique Endo®, 5000 IU/ml, Schering-
Plough) were as described elsewhere [15] or were determined in
preliminary experiments, as for the doses and exposure times for rFSH
(GONAL-F Follitropin Alfa, 450 IU/0.75 ml, MERCK). For each treatment,
the controls contained an equivalent volume of the carrier solution and
were conducted in parallel. After treatment, cells were rinsed with ice-
cold PBS and treated with trypsin. Cells were lysed in ice-cold RIPA
buffer (10 mmol/l Tris-HCl pH 7.5, 150 mmol/l NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate) supplemented with 25 mmol/l sodium
ﬂuoride, 1% protease inhibitor and 0.5 mmol/l sodium orthovanadate.
For RNA extraction after treatment, cells were rinsed with ice-cold PBS
and lysed with Trizol (Invirogen). Equal amounts of proteins from cell
lysates were subjected to SDS-PAGE in 10% polyacrylamide gels. The
bands obtained were transferred onto nitrocellulose membranes,
which were blocked and incubated overnight at 4 °C with a 1:200
dilution of a goat anti-human pERK1/2 IgG (Santa Cruz Biotechnology,
Santa Cruz, CA). Incubation with the primary antibody was followed
by incubation with the corresponding horseradish peroxidase-labeled
secondary antibody at a 1:1000 dilution for 1 h at room temperature.
Immunocomplexes were visualized by enhanced chemiluminescence
(Pierce Perbio Sciences, Brebières, France). All membranes were
reprobed with rabbit anti-human antibodies against ERK1/2 (1:200),
as a loading control. ERK1/2 and pERK1/2 levels were explored in all
of the cell lines extracted from the six patients with endometriosis.
The values shown are means ± SEM (*P b 0.05).
2.6. In vitro cell proliferation and viability assays
We assessed the proliferative effect of hCG on control endometrial
cells and EEC, by treating the cells with various concentrations of hCG
(0, 2.5, 5, 10, 20 IU/ml) for 48 h and assessing cell proliferation by
measuring [3H]thymidine incorporation during the last 16 h of culture.
Results are expressed as the ratio of cpm for treated cells versus cpm
for untreated cells in three experiments. The red dotted line
corresponds to untreated cells. (n = 3 independent experiments;
*P b 0.05; **P b 0.01).
2.7. Statistical analysis
All statistical analyses were performed with XLSTAT software. Para-
metric analyses were carried out as the data for all experiments were
normally distributed.We used Student's t-test for quantitative variables
and Pearson's χ2 or Fisher's test for qualitative variables, as appropriate.
A one-way ANOVA was conducted for comparisons of more than two
groups. If group means were signiﬁcantly different on one-way
ANOVA (P b 0.05), we carried out pairwise comparisons with Student-
Newman-Keuls post hoc tests. A two-way ANOVA was used when two
or more datasets were compared for different factors. Results are
means ± SD. P b 0.05 was considered signiﬁcant (*P b 0.05; **P b 0.01).3. Results
All patients of this study population have been described elsewhere
[10] and consisted of 69 patients originating from the same cohort,
including 38 with endometriosis and 31 disease-free control women,
the same number of patients being in proliferative and in secretory
phases for all experiments. The same results were obtained when
OMA or DIE were studied.
3.1. Aberrant expression of the FSHR in half of eutopic and all ectopic
endometriosis
The FSHRplays a key role in the ovary, by inducing aromatase, which
converts androgens into estrogens. We used reverse transcription-
quantitative PCR (RT-qPCR) on controls and eutopic or ectopic
endometriotic tissues [10] to analyzed FSHR mRNA levels. We
performed individual comparative studies on paired eutopic andectopic
lesions.
In half of eutopic endometrioses studied, aberrant FSHR mRNA levels
were detected (6 times higher than in control women; P ≤ 0.05) (Fig.
1A). We deﬁned this eutopic FSHR positive group of patients as group A,
and the other half devoid of eutopic FSHR as group B patients (Fig. 1A).
In all the ectopic endometriotic tissues studied, FSHR mRNA levels
were highly upregulated. They were much higher in ectopic lesions
from group A than from group B patients (239 and 29 times higher
than control levels, respectively (Fig. 1B). We conﬁrmed the expression
of the FSHR protein in tissue samples by immunohistochemistry using a
monoclonal antibody. The FSHR stainingwasweakly detected in the ep-
ithelial cells of control patients, but much stronger in ectopic
endometriotic lesions (Fig. 1C). Stromal cells were also labeled, but
less strongly. The FSHR protein was also detected in the endometrial
blood vessels of ectopic endometriotic tissues, but not in control blood
vessels (Fig. 1C).
3.2. Aberrant expression of othermarkers of ovarian differentiation, the LHR
and INSL3 in endometriosis
To determine whether FSHR expression in endometriosis was
accompanied by a broader pattern of inappropriate “ovarian-like”
differentiation, we studied other speciﬁc ovarian genes which might be
concomitantly aberrantly expressed in eutopic or ectopic endometriotic
tissues. In ovaries, the LHR is critical for androgen synthesis, which serves
as substrates for estrogen production by aromatase. In control
endometria and eutopic endometriotic tissues, RT-qPCR detected very
low levels of LHR transcripts with no signiﬁcant differences between
groups (Fig. 1A). Interestingly, ectopic endometriotic lesions of a subset
of patients (6/28 (21%)) hadmuch higher LHRmRNA levels than controls
(N10,000-fold induction (P ≤ 0.05)). We deﬁned these LHR and FSHR
positive ectopic endometrioses as group C (Fig. 1B). Immunohistochem-
istry using amonoclonal antibody revealed a faint LHR labeling in control
epithelial cells with a strong labeling detected in the epithelial cells of ec-
topic endometriotic tissue from a representative patient (Fig. 1C). Stro-
mal cells were weakly labeled.
The ovarian hormone INSL3 plays an important role in maintaining
androgen production by ovarian theca cells by inducingCYP17 steroido-
genic enzyme [16] and modulates both LH and FSH actions [16,17].
INSL3 is regulated by LH in ovarian theca cells [18]. We found that
INSL3 was aberrantly expressed in group A eutopic endometriosis
(Fig. 1A) and all ectopic lesions (Fig. 1B) together with CYP17 tran-
scripts. The highest levels of INSL3 (290–fold; P ≤ 0.05) transcripts
were found in ectopic group C endometriosis also aberrantly expressing
LHR (Fig. 1B). No immunohistochemical labeling of INSL3 protein was
detected in control endometria. By contrast, INSL3 protein levels were
abnormally high in the epithelial cells of ectopic endometriotic tissues
(Fig. 1C). Stromal cells were not labeled.
Fig. 1. Aberrant expression of the FSHR and the LHR in a broad ovarian-like differentiation in endometriosis. A and B. RT-qPCR analysis of FSHR, LHR, INSL3 and steroidogenic enzymes
CYP11, CYP17, CYP19 transcripts from eutopic (n = 16) (A) and ectopic (n = 16) (B) endometriotic tissues. Y axis: mRNA expression relative to control. The values shown are
means ± SEM (*P b 0.05). C. Left: pre-immune IgG were used as controls. Right: immunohistochemical staining of FSHR, LHR and INSL3 with speciﬁc antibodies in control (disease-
free) endometria (n= 10) and ectopic endometriotic tissues (n= 10). The arrow indicates a vessel. Illustrative pictures shown are representative of the median level of staining for
each protein studied except for the LHR for which an aberrant expression of proteins is detected in only 21% of patients. All scale bars indicate 100 μm.
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same steroidogenic cascade as in ovaries, and their signaling involves the
ERK 1/2 pathway
To verify the functionality of FSHR and LHR in endometriotic cells,
we used primary cultures of epithelial cells derived from ectopicendometriotic tissue obtained from DIE (n = 12) or from control
women (n= 6) [13]. We ﬁrst study the signaling of these receptors in
EEC after stimulation of each receptor by the cognate hormone. In ova-
ries, FSHR and LHR signaling involve mainly the cAMP pathway [7].
However no stimulation of the PKA-cAMP pathway by rFSH or hCG
was observed in endometriotic cells (data not shown). It has been
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human endometrial HES cells that the immediate signal transduction
pathways induced by hCG are cAMP independent and stimulate phos-
phorylation of ERK 1/2 [15]. EEC treated with hCG or rFSH had higher
levels of phosphorylated ERK (pERK) 1/2 with maximal effect after
10 min (respectively 5.91-fold and 3.23-fold increase in pERK/ERK 1/2
ratio (P ≤ 0.05)) (Fig. 2A). We can conclude that the ERK 1/2 pathway
mediates signaling by both hormones in EECs.
FSHR and LHR function in the ovary is dependent on the induction of
steroidogenic enzymes. In all endometriotic tissues aberrantly express-
ing the FSHR, aromatase (CYP19A1) mRNA levels were concomitantly
upregulated. In eutopic endometrioses of group A, but not group B,
CYP19A1 mRNA levels were upregulated (9.5 fold higher than controls
(P ≤ 0.05)) (Fig. 1A). In all ectopic lesions the FSHR was upregulated
to an even greater extent, and CYP19A1 transcript levels were very
high, particularly in group A patients (980-fold in ectopic group A,
310-fold in ectopic group B (P ≤ 0.05)) (Fig. 1B). The parallel increase
in FSHR and CYP19A1 transcript levels suggests that the FSHR induces
aromatase in endometriosis, as in ovaries. CYP17 transcripts were also
upregulated in eutopic endometrioses from group A whereas
CYP11A1 transcripts were not (Fig. 1A). Thus, the enzymatic machinery
in eutopic endometriosis may be able to convert exogenous circulating
androgens into estrogens.
In ectopic endometriosis CYP17 transcript levels were highly upreg-
ulated (79 and 19-fold in groups A and B, P ≤ 0.05), associated with a
moderate but signiﬁcant increased expression of CYP11A1 transcripts.
Thus,mRNAs for androgen-synthesizing enzymes are present in ectopic
lesions, together with aromatase, potentially yielding complete in situ
steroidogenesis. In an interesting way, when the LHR was expressed
(group C) the strongest induction of transcripts encoding the completeFig. 2. The FSHR and LHR are functional in endometriosis inducing the same steroidogenic casca
endometriotic cells (EECs) stimulated by rFSH (n=6) or hCG (n=6). ERK 1/2 phosphorylation
(*P b 0.05). B. RT-qPCR analysis of EECs stimulated with rFSH (n= 6) or hCG (n= 6). Y axis:
response to hCG in EECs and control epithelial endometrial cells (n=6 for each cell type). Cells
proliferation was assessed by measuring [3H]thymidine incorporation during the last 16 h of cu
cells. Y axis: proliferation relative to untreated cells. The red dotted line corresponds to untreasteroidogenic cascade was detected (69,792-fold for CYP19A1, 26,519-
fold for CYP17 and 917-fold for CYP11A1 (P ≤ 0.05)) (Fig. 1B).
To know whether the signaling pathway of gonadotropins in EEC
was functional, we studied the induction by FSH or hCG of the
complete steroidogenic cascade and ovarian steroidogenic factors.
We found that recombinant FSH (rFSH) induced the accumulation
of aromatase transcripts (3.5-fold, p ≤ 0.05) in EEC as in ovaries
(Fig. 2B). hCG upregulated transcripts encoding androgen-
synthesizing enzymes CYP11A1, CYP17 (1.8 and 3.5-fold; P ≤ 0.05;
Fig. 2C) and INSL3 (5.7-fold, P ≤ 0.05), a potent stimulator of
CYP17, as in ovaries [18]. Interestingly hCG also induced FSHR tran-
scripts (5.8-fold) as in ovaries [7] (Fig. 2B).
ERK 1/2 belongs to theMAPK family proteinswhich are keys regula-
tor ofmanyprocesses including cellular growth, differentiation, cell sur-
vival or immune response [19]. In endometrial cancer cells, it has been
shown that the LHR controls cell proliferation and could represent a
prognostic factor and a new therapeutic target in endometrial cancer
[20,21]. Endometriosis shares features common with cancers [1,5]. We
thus aim to study comparatively the effect of hCG on the proliferation
of EEC. We show that hCG yielded a dose-dependent increase in the
proliferation of EEC but not of control endometrial cells from disease-
free women. Themaximum increase in proliferation relative to untreat-
ed cells was 44% (P b 0.05) (Fig. 2C). This experiment highlights the
functional proliferative effect of the LHR in EEC, similarly to what was
shown in endometrial cancer cells [20,21].
Altogether these experiments show that the FSHR and LHR are
functional in EEC. Their signaling involves the ERK 1/2 pathway, the
LHR induces EEC proliferation and both receptors induce the expression
of the complete steroidogenic cascade and ovarian steroidogenic factors
transcripts also induced by the same receptors in ovaries.de as in ovaries. A. Kinetics of phospho-ERK 1/2 induction in primary cultures of epithelial
was quantiﬁed by densitometrywith the ImageJ software (pERK/ERK 1/2 fold induction)
mRNA expression relative to control. Values are means ± SEM (*P b 0.05). C. Proliferative
were treated with various concentrations of hCG (0, 2.5, 5, 10, 20 IU/ml) for 48 h and cell
lture. Results are expressed as the ratio of cpm for treated cells versus cpm for untreated
ted cells. (n= 3 independent experiments; *P b 0.05; **P b 0.01).
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To investigate the mechanism underlying this aberrant expression
of the FSHR in endometriosis, we analyze the expression of GATA4
and GATA6 transcription factors, which are involved in gonadalFig. 3. Ovarian transcription factors are aberrantly expressed in endometriosis and induced by
eutopic (A) and ectopic (B) endometric tissues. Y axis :mRNAexpression relative to control. The
antibodies of GATA-4/6 in control endometria (n=10) and ectopic endometriotic tissues (n=1
or hCG (n= 6). Y axis : mRNA expression relative to control. Values are means ± SEM (*P b 0differentiation and in the onset of FSHR and LHR genes expression in
the ovaries [22].
Eutopic endometriotic tissues fromgroupA but not fromgroup B pa-
tients, displayed aberrant GATA6/4 expression (respectively 12.4 and
2.2 fold stronger than in controls; P ≤ 0.05; Fig. 3A). All ectopic
endometriotic tissues had very high levels of FSHR expression, togethergonadotropin receptors. A and B. RT-qPCR analysis of GATA4 and GATA6 transcripts from
values shown aremeans±SEM(*P b 0.05). C. Immunohistochemical stainingwith speciﬁc
0). All scale bars indicate 100 μm.D. RT-qPCR analysis in EEC stimulatedwith rFSH (n=6)
.05).
149B. Fouquet et al. / BBA Clinical 6 (2016) 143–152with dramatic induction of GATA4 and GATA6 mRNAs, higher in group
A patients (respectively 1779- and 293-fold induction in ectopic group
A; and 356- and 74-fold in ectopic group B; (P ≤ 0.05) Fig. 3B). No
difference in the accumulation of transcripts for GATA 4/6 is found
between patients from ectopic groups A and C, so we merged both
groups in group A.
On immunohistochemistry labeling for GATA4 was weak and no
labeling for GATA6 was observed in control endometria, whereas label-
ing for both GATA4 and GATA6 was intense especially in the nucleus of
epithelial endometriotic cells (Fig. 3C). Stromal cells were also labeled,
but less strongly.
In EEC both rFSH and hCG signiﬁcantly increased GATA4/6 (by 5.1-,
9.1 -fold, respectively, for rFSH; and by 4.1-, 5.3- fold for hCG; (P ≤ 0.05))
(Fig. 3D). These results suggest that a positive autoregulatory loop,
similar to that in ovaries [23] operates in endometriotic cells, favoring
estrogen-dependent disease progression. FSH and LH also induced at a
lesser extent SF1 transcript levels (Fig. 3D).3.5. FSHR and LHR regulate vascular and inﬂammatory factors in
endometriotic cells
Angiogenesis and inﬂammation are important part in the physiopa-
thology of endometriosis, dissemination of endometriotic lesions, and
in the development of pain [1,2]. It has been shown previously that
FSH could play a role in angiogenesis and hCG in inﬂammation in
different cell types. Apart from induction of aromatase, rFSH induces
VEGF mRNA levels in human granulosa cells [24]. FSH promotes angio-
genesis in placental endothelial cells [25]. FSHR is also widely present in
tumor blood vessels [9]. It is thought to be angiogenic, favoring tumor-
igenesis [8,9]. Endothelial FSHR expression in breast cancer is associated
with vascular remodeling at the tumor periphery [26]. hCG induces ac-
cumulation of inﬂammatory factors transcripts in different cell types. In
endometrial epithelial cells hCG increases PGE2 release as the possible
result of cyclooxygenase-2 activation [15,27]. Studies of genetically
modiﬁed LHR-knockout mice have shown that LH or hCG can activate
PTGS2 gene which plays an essential role in implantation [28]. It has
been shown that human decidual luteal and endometrial macrophages
contain LHR [29].
We thus wondered whether these receptors could contribute to the
pathogenesis of endometriosis not only through the induction of
estrogen-dependent proliferative effect but also through inﬂammation
and angiogenesis. We observe an upregulation of vascular factors tran-
scripts (VEGFC, VEGFD and EGVEGF) in eutopic endometriosis even
more enhanced in ectopic endometriosis when the FSHR is more
strongly up-regulated. There is also an up-regulation of inﬂammatory
factors and their receptors transcripts (PTGS2 and PTGER2, 3 and 4) in
eutopic and ectopic endometrioses (Fig. 4 A and B).
No difference in the accumulation of transcripts for vascular or in-
ﬂammatory factors is found between patients from ectopic groups A
and C, so we merged both groups in group A.
We also studied the induction of angiogenic and inﬂammatory
factors by FSH and hCG in primary culture of epithelial endometriotic
cells. In EEC, rFSH induced a strong increase in mRNA levels for the
angiogenic factors VEGFD and EGVEGF (7.85- and 5.18-fold induction;
P ≤ 0.05) as in ovarian cells [24] (Fig. 4C).
These ﬁndings suggest that FSHmight play a novel angiogenic role in
endometriotic cells similar to that proposed for tumor cells [8,9]. We
found that hCG induced accumulation of inﬂammatory factors
transcripts PTGS2, PTGER2, PTGER3 and PTGER4 (2.85-, 10.59-, 18.8-,
and 7.37-fold induction respectively, P ≤ 0.05) in EEC (Fig. 4C). This
should lead to an increase in prostaglandin production, contributing to
inﬂammation.
We show that in EEC rFSH induces mainly vascular while hCG
induces inﬂammatory factors. These observations in EEC support a
contributive role for FSH and LH receptors in the angiogenesis andinﬂammation found in endometriosis in addition to their hormonal
role (Figs. 4 and 5).
Altogether our results suggest an alternative physiopathological
mechanism of endometriosis, involving a broad ovarian-like differenti-
ationwith expression of GATA4/6 transcription factors, INSL3, and aber-
rant FSHR and LHR expression and function in a subset of endometriotic
tissues leading to in situ production of E2 (Fig. 5).
4. Discussion
Endometriosis is a major public health problem due to the infertility
and/or chronic pelvic pain it causes [1–4]. There is currently no biolog-
ical markers for early diagnosis which is delayed about 7–10 years
after the apparition of the ﬁrst symptoms during surgery. Improvement
of our understanding of the pathophysiology of endometriosis is
therefore required, for the development of novel methods for early di-
agnosis. This work highlights a novel pathophysiological mechanism
in endometriosis with a global ovarian pattern of differentiation in a
subset of eutopic and all ectopic endometrioses.
The mechanism of estrogen production by endometriotic tissue is
poorly understood. One possible mechanism of E2 production is
ovarian-like differentiation of the endometriotic tissue, with abnormal
gonadotropin receptors expression and function. Indeed aberrant
FSHR expression was detected in half eutopic endometria studied
(group A). In group A patients, there is a concomitant aberrant expres-
sion of other genes normally expressed in ovaries especially aromatase,
INSL3 and transcription factors GATA4/6. Eutopic group A is thus called
“ovarian-like differentiated” while group B patients do not exhibit
eutopic ovarian-like differentiation. In eutopic endometriotic tissues
from group A patients, circulating androgensmay therefore be convert-
ed to estrogens in situ by aromatase, at early stages of disease. In all
disseminated endometriosis, strong FSHR expression and high levels
of aromatase transcripts are observed. The FSHR is functional, as FSH
upregulates aromatase transcripts in EEC, consistent with concomitant
upregulation of aromatase and FSHR during endometriosis, as in
ovaries. Recently, a faint expression of the FSHR protein was detected
in ectopic endometriotic glandular epithelial or stromal cells in a
low proportion of patients with endometriosis (≤ 25%) [30]. Another
recent study reports functional expression of the FSHR in ectopic
endometriotic lesions inducing aromatase [31]. However both reports
did not study other ovarianmarkers allowing complete in situ steroido-
genesis in endometriosis as well as the expression of transcription
factors triggering endocrine function in ovaries [30,31]. Eutopic
endometrium was not studied in these reports. In group A patients, an
ovarian-like differentiation is detected before dissemination of
endometriotic lesions. This observation could be useful to improve
early diagnosis of endometiosis.
We found that eutopic tissues from patients with endometrioses
displayed no upregulation of LHR transcripts [32]. However a high ex-
pression of the LHR was detected in a susbet of ectopic endometriosis
(~21%, group C patients) together with a dramatic increase in
androgen-synthesizing enzymes transcripts. The LHR is also functional,
hCG upregulates androgen-synthesizing enzymes transcripts in EEC,
consistent with concomitant upregulation of CYP11A1, CYP17 and the
LHR during endometriosis, as in ovaries.
Altogether these results show that both FSHR and LHR are functional
in endometriotic cells, inducing the same target genes as in the ovaries,
yielding a full steroidogenic cascade able to synthesize in situ androgens
and estrogens necessary for autocrine proliferation and growth.
The aberrant expression of the ovarian steroidogenic factor INSL3
also parallels the increased expression of the FSHR in endometriotic
lesions. INSL3 is a circulating peptide hormone of the relaxin-insulin
family involved in tumor cell growth, differentiation, invasion and neo-
vascularization [33]. INSL3 induces CYP17 expression in the ovary,
maintaining androgen production [16]. The highest levels of INSL3 tran-
scripts were found in group C endometriosis also aberrantly expressing
Fig. 4. FSHR induces vascular and LHR induces inﬂammatory factors in endometriotic cells. A and B. RT-qPCR analysis from eutopic (n= 16) (A) and ectopic (n= 16) (B) endometric
tissues. Y axis: mRNA expression relative to control. The values shown are means ± SEM (*P b 0.05). C. RT-qPCR analysis in EECs stimulated with rFSH (n= 6) or hCG (n= 6). Y axis:
mRNA expression relative to control. Values are means ± SEM (*P b 0.05).
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genic cascade, involving CYP17 and CYP11. We found that hCG
upregulated INSL3 transcripts in EEC. These observations in EECs are
concordant with what is known in ovarian theca cells where INSL3 is
induced by LH (13) and induces CYP17 expression [16]. Thus it seems
that ovarian regulations of INSL3 (by LH) and of androgen synthesizing
enzymes (by INSL3 and LH) could be aberrantly reproduced in
endometriosis.
GATA4 and 6 are transcription factors involved in gonadal differenti-
ation and in the regulation of FSHR and LHR genes expression in the
ovaries [22]. The loss of GATA4/6 from granulosa cells blocks FSHR
expression, leading to female infertility [34]. Women lacking FSHR
have low levels of GATA4 expression [22]. In mice lacking GATA4 or
GATA4/6, expression levels of LHR and also CYP17, CYP19A1 and
CYP11A1 are signiﬁcantly lower than in controls, and FSHR is undetect-
able [34]. The onset of ectopic adrenal GATA4 production coincideswith
LHR expression and the occurrence of adrenocortical tumors [23].
Genome-wideDNAmethylation analysis predicted an epigenetic switchfor GATA factor expression in cultured ectopic endometriotic stromal
cells [35]. There is also evidence that FSH and LH regulate gonadal
GATA gene expression [22]. Thus, the parallel increase in GATA4/6 tran-
scription factors and gonadotropin receptors levels strongly suggests
that these transcription factors regulate FSHR and LHR expression in
endometriosis, as in ovaries [22]. GATA 4 and GATA6 are induced by
the FSHR and LHR in EEC. These results suggest that a positive
autoregulatory loop similar to that in ovaries operates in endometriotic
cells, favoring estrogen-dependent disease progression [23].
5. Conclusions
This work highlights a novel pathophysiological mechanism in en-
dometriosis. A broad ovarian-like differentiation is observed in half
eutopic tissues and all disseminated ectopic lesions of endometriosis
with the aberrant expression of transcription factors GATA4 and
GATA6 triggering ovarian differentiation and gonadotropin receptors
expression in the ovary. A positive feedback loop probably occurs
Fig. 5.Model of ovarian-like differentiation in endometriosis. In red, genes upregulated in eutopic endometriosis; in blue, additional genes upregulated in ectopic endometriosis. The
aberrant production of GATA4/6 factors may trigger FSHR expression at the start of the disease in eutopic tissues, in a subset of patients (group A), and during disease progression in
all ectopic lesions (groups A and B). Together with INSL3, these molecules may induce partial steroidogenesis in situ especially through aromatase induction. In a subset of ectopic
lesions, strong GATA4/6 expression also induces aberrant LHR upregulation (group C), resulting in the strongest induction of the complete steroidogenic cascade and the highest levels
of INSL3 transcripts. The upregulation of GATA4/6 factors by FSHR and LHR in endometriotic cells may result in an autoregulatory loop favoring estrogen-dependent disease
progression. FSHR and LHR also have angiogenic and inﬂammatory properties, respectively.
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ovaries, enhancing the production of the steroidogenic cascade. The
FSHR and the ovarian hormone INSL3 which modulates LH and FSH
action in ovaries are aberrantly expressed concomitantly with GATA 4/
6. FSH induces aromatase in endometriotic cells. Partial steroidogenesis
with aromatization of circulating androgens into estrogens can there-
fore occur. In a subset of disseminated lesions, the LHR is also highly
expressed and induces androgen synthesizing enzymes and INSL3,
yielding complete in situ steroidogenesis, as in ovaries. FSH induces
vascular while hCG iduces inﬂammatory factors in EEC. Apart from
their hormonal role the FSHRand LHRmight also contribute to the path-
ogenesis of endometriosis through inﬂammation and angiogenesis.
The ovarian-speciﬁc markers highlighted in this study could open
new avenues, in the future, in the development of an early non-
invasive diagnostic method for a subset of patients with endometriosis.
Further studies in a larger population of patients are required to
establish the proportion of patients with an eutopic “ovarian-like
phenotype” at early stage of the disease, characterized by the expression
of the ovarian genes highlighted here. RT-qPCR and immunohistochem-
ical staining revealed high expression of FSHR, INSL3, GATA4/6 in all
ectopic endometrioses, suggesting that this pattern might give new
tools for the diagnosis of the disease.Conﬂict of interest
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